OR WAIT null SECS
Inpefa to support multiple cardiovascular issues.
Lexicon, a biopharmaceutical company, has received FDA approval for Inpefa, a once-daily oral tablet designed to reduce the risk of cardiovascular issues including heart failure, type 2 diabetes, and chronic kidney disease. The company plans on setting the medicine’s wholesale acquisition cost comparable to existing branded heart failure medications.
“The approval of INPEFA along with the breadth of the label, is a major milestone in Lexicon’s path to fulfilling its mission of pioneering medicines that transform patients’ lives,” said Lonnel Coats, CEO, Lexicon. “We expect this important innovation to be commercially available in the U.S. market by the end of June 2023.”